Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.3728 -0.4272 (-1.1%) Market Cap: 5.60 Bil Enterprise Value: 4.90 Bil PE Ratio: 0 PB Ratio: 18.90 GF Score: 70/100

Ionis Pharmaceuticals Inc at Needham Healthcare Conference Transcript

Apr 09, 2019 / 04:50PM GMT
Release Date Price: $83.72 (-2.81%)
Chad Jason Messer
Needham & Company, LLC, Research Division - Senior Analyst

Good afternoon, everyone. Thanks for joining us. My name is Chad Messer. I'm a senior biotech analyst here at Needham & Company. I'm joined today by Beth Hougen, Chief Financial Officer; and Wade Walke, Vice President of Investor Relations at Ionis Pharmaceuticals. And I'm going to hand it to Beth to get it started.

Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Senior VP of Finance & CFO

Great. Thank you. Thank you for having us. We have been on a roll lately. It's been just an exciting time at Ionis. We have 2 drugs that are commercial now: SPINRAZA and TEGSEDI, both for rare diseases, both fatal rare diseases. And WAYLIVRA, our third drug should be approved here in Europe within the next couple of months or so. So a very exciting time in that we're building our financial story with commercial revenues now. Our pipeline continues to perform. We have 4 drugs that will be in pivotal studies this year. Two already have started, one for Huntington's and one for SOD1, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot